Suppliers and packagers for lisinopril

lisinopril

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Annora Pharma	LISINOPRIL	lisinopril	TABLET;ORAL	075903	ANDA	Camber Pharmaceuticals, Inc.	31722-172-31	95238 TABLET in 1 CARTON (31722-172-31)	2021-08-17
Annora Pharma	LISINOPRIL	lisinopril	TABLET;ORAL	075903	ANDA	Camber Pharmaceuticals, Inc.	31722-172-01	100 TABLET in 1 BOTTLE (31722-172-01)	2021-08-17
Annora Pharma	LISINOPRIL	lisinopril	TABLET;ORAL	075903	ANDA	Camber Pharmaceuticals, Inc.	31722-172-05	500 TABLET in 1 BOTTLE (31722-172-05)	2021-08-17

Lisinopril Drug Supply Chain Analysis

Last updated: February 19, 2026

Lisinopril, a widely prescribed angiotensin-converting enzyme (ACE) inhibitor for hypertension and heart failure, relies on a complex global supply chain for its active pharmaceutical ingredient (API) and finished dosage forms. Key suppliers for lisinopril API originate primarily from China and India, with manufacturing capabilities also present in Europe. Finished dosage form manufacturing is more geographically dispersed.

What are the primary suppliers of lisinopril API?

The manufacturing of lisinopril API is concentrated in a few key regions, with a significant portion sourced from China and India due to cost efficiencies and established chemical synthesis infrastructure. European manufacturers also contribute, often focusing on higher-purity or specialized grades.

• China: Holds a dominant position in lisinopril API production. Multiple manufacturers supply the global market, with production capacity estimated to be substantial. Specific companies include Zhejiang Huahai Pharmaceutical Co., Ltd. and Zhejiang NHU Co., Ltd., known for their large-scale API production. These companies often leverage economies of scale to offer competitive pricing.
• India: Is another major global supplier of lisinopril API. Indian pharmaceutical companies have a strong track record in API manufacturing, benefiting from a well-developed pharmaceutical ecosystem and skilled workforce. Key players include Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories, and Cipla. These companies often adhere to stringent regulatory standards, facilitating export to regulated markets.
• Europe: While less dominant than Asia in sheer volume, European manufacturers produce lisinopril API, often catering to specific quality requirements or niche markets. Companies in countries like Germany and Italy may offer specialized production capabilities.

Table 1: Leading Geographic Regions for Lisinopril API Supply

Region	Key Suppliers (Examples)	Notes
China	Zhejiang Huahai Pharmaceutical Co., Ltd., Zhejiang NHU Co., Ltd.	Significant production volume, cost-competitive.
India	Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories, Cipla	Strong regulatory compliance, established pharmaceutical expertise.
Europe	Various manufacturers in Germany, Italy	May focus on specialized grades or higher-purity requirements.

Who are the major manufacturers of lisinopril finished dosage forms?

The production of finished lisinopril dosage forms (tablets) is more widely distributed than API manufacturing, reflecting the final stages of drug formulation and packaging, which are often conducted closer to end markets to manage logistics and meet local regulatory requirements.

• North America: A significant number of generic drug manufacturers in the United States and Canada produce lisinopril tablets. Companies like Teva Pharmaceuticals USA, Inc., Viatris Inc. (formed by the merger of Mylan and Pfizer's Upjohn), and Aurobindo Pharma USA, Inc. are major players. These manufacturers often focus on high-volume production of the most common strengths (e.g., 5 mg, 10 mg, 20 mg).
• Europe: European pharmaceutical companies also manufacture lisinopril tablets for their respective markets and for export. Companies like Sandoz (part of Novartis), Sanofi, and Bristol Myers Squibb have a presence in this segment. The regulatory landscape in Europe, governed by the European Medicines Agency (EMA), mandates specific manufacturing and quality controls.
• Asia: Beyond API production, some Asian companies also formulate and manufacture lisinopril tablets, serving domestic and international markets. These include companies in India and other regions that have robust finished dosage form manufacturing capabilities.

Table 2: Major Companies Manufacturing Lisinopril Finished Dosage Forms (Examples)

Region	Key Manufacturers (Examples)
North America	Teva Pharmaceuticals USA, Inc., Viatris Inc., Aurobindo Pharma USA, Inc.
Europe	Sandoz, Sanofi, Bristol Myers Squibb
Asia	Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories, Cipla (India)

What are the key regulatory considerations for lisinopril supply?

The supply chain for lisinopril is subject to stringent regulatory oversight to ensure product quality, safety, and efficacy. This oversight applies to both API manufacturing and finished dosage form production.

• Good Manufacturing Practices (GMP): All manufacturing sites for lisinopril API and finished products must adhere to GMP standards established by regulatory bodies such as the U.S. Food and Drug Administration (FDA) [1] and the EMA [2]. GMP compliance ensures consistent production and quality control.
• Drug Master Files (DMFs) and Active Substance Master Files (ASMFs): API manufacturers must submit detailed documentation about their manufacturing processes, quality controls, and impurity profiles to regulatory agencies. These DMFs (in the US) or ASMFs (in Europe) are reviewed by authorities as part of the drug approval process. For lisinopril, these filings are critical for generic manufacturers seeking to use API from specific suppliers.
• Inspections and Audits: Regulatory agencies conduct periodic inspections of manufacturing facilities to verify GMP compliance. Pharmaceutical companies also conduct their own audits of API suppliers to ensure the reliability and quality of their raw materials.
• Impurity Control: Regulatory bodies have increasingly focused on controlling impurities in pharmaceuticals, including nitrosamine impurities. Manufacturers of lisinopril must demonstrate robust analytical methods and process controls to minimize and monitor any potential impurities. Guidance documents from the FDA and EMA outline acceptable limits and testing requirements [3].
• Supply Chain Security and Traceability: Regulations are evolving to enhance supply chain security and traceability, particularly in response to counterfeit drug concerns. This includes measures like serialization and track-and-trace systems to follow drug products from manufacturing to the patient.

What are the critical raw materials and intermediates for lisinopril synthesis?

The chemical synthesis of lisinopril involves several key raw materials and intermediates. The reliable sourcing and quality control of these components are vital for uninterrupted API production.

• L-Lysine: A fundamental amino acid and a direct precursor in the synthesis of lisinopril. The purity and availability of L-Lysine are critical.
• Ethyl 4-phenylbutyrate: An ester used in the multi-step synthesis. Its quality impacts the efficiency and purity of subsequent reactions.
• 2-Propanol (Isopropyl Alcohol): Used as a solvent in various synthesis steps.
• Acetic Anhydride: Employed as an acetylating agent in specific reaction pathways.
• Other Reagents and Solvents: The synthesis also requires a range of other chemical reagents and solvents, such as hydrochloric acid, sodium hydroxide, methanol, and ethyl acetate. The specifications and sourcing of these materials are managed by API manufacturers.

The synthesis route for lisinopril can vary slightly between manufacturers, leading to different intermediate products. However, common starting materials and reaction types are employed globally. Fluctuations in the cost or availability of these raw materials can directly impact the price and supply of lisinopril API.

What are the common dosage strengths and forms available?

Lisinopril is predominantly available as an oral tablet. The most common dosage strengths are designed to allow for flexible titration of therapy based on patient response and medical guidelines.

• Dosage Strengths:

  • 2.5 mg
  • 5 mg
  • 10 mg
  • 20 mg
  • 30 mg
  • 40 mg

• Dosage Forms:

  • Oral Tablets: This is the standard and most widely used form. Tablets are typically scored to allow for easy splitting into lower doses if necessary.
  • Oral Solution: Less common, but available for patients who have difficulty swallowing tablets.

The formulation of these tablets involves excipients such as microcrystalline cellulose, calcium phosphate, magnesium stearate, and starch, which are also sourced from various chemical suppliers.

What are the typical lead times for lisinopril API and finished products?

Lead times for pharmaceutical supplies are influenced by manufacturing complexity, inventory levels, regulatory approvals, and shipping logistics.

• Lisinopril API: Lead times for lisinopril API can range from 8 to 16 weeks from order placement to delivery. This duration accounts for batch production schedules, quality control testing, and international shipping. API manufacturers often maintain buffer stocks, but significant orders may require dedicated production runs.
• Lisinopril Finished Dosage Forms: For finished tablets, lead times are generally shorter, typically ranging from 4 to 10 weeks. This reflects the fact that the API is already produced, and the manufacturing process involves formulation, tablet compression, coating (if applicable), packaging, and final quality release. Distribution and logistics add further time to reach the end customer.

Factors that can extend these lead times include:

• Unexpected API quality issues or recalls.
• Raw material shortages affecting API synthesis.
• Increased demand due to seasonal fluctuations or public health alerts.
• Port congestion or shipping disruptions.
• Extended regulatory review periods for new suppliers or manufacturing changes.

How do geopolitical factors and trade policies impact lisinopril supply?

The global nature of the lisinopril supply chain makes it susceptible to geopolitical events and trade policies. Disruptions in one region can have cascading effects worldwide.

• Trade Tariffs and Duties: Imposition of tariffs on chemical intermediates or finished pharmaceutical products between countries can increase manufacturing costs and, consequently, the price of lisinopril. For example, changes in U.S.-China trade relations have historically affected the cost of APIs sourced from China.
• Export/Import Restrictions: Governments may implement export restrictions on critical pharmaceutical ingredients during times of national emergency or increased domestic demand, impacting global availability. Similarly, import regulations and customs procedures can cause delays.
• Geopolitical Instability: Conflicts or political instability in key manufacturing regions (e.g., China, India) can disrupt production, logistics, and supply chains. This includes disruptions to transportation networks and potential impacts on labor availability.
• Sanctions: International sanctions imposed on specific countries can limit trade and access to essential raw materials or finished goods, forcing companies to seek alternative, potentially more expensive, suppliers.
• Intellectual Property and Generic Competition: While lisinopril is a well-established generic drug with expired patents, the regulatory pathways for generic approval and market entry are influenced by intellectual property laws and the competitive landscape in different jurisdictions.

Companies managing lisinopril supply chains continuously monitor these factors and may diversify their supplier base to mitigate risks associated with over-reliance on a single region or country.

What is the role of contract manufacturing organizations (CMOs) in the lisinopril supply chain?

Contract Manufacturing Organizations (CMOs) play a significant role in both lisinopril API and finished dosage form production. They offer specialized manufacturing capabilities and capacity, allowing pharmaceutical companies to outsource production and focus on R&D and marketing.

• API Manufacturing: CMOs with expertise in complex organic synthesis are contracted by pharmaceutical companies to produce lisinopril API. These CMOs operate under strict GMP guidelines and often have large-scale production facilities.
• Finished Dosage Form Manufacturing: Many pharmaceutical companies, especially smaller ones or those entering the generic market, utilize CMOs for the formulation and packaging of lisinopril tablets. This includes processes like granulation, compression, coating, blister packing, and bottle filling.
• Specialized Services: CMOs may also offer specialized services such as analytical testing, stability studies, and regulatory support, further streamlining the drug development and manufacturing process.

The use of CMOs provides flexibility, cost-effectiveness, and access to specialized technology and expertise. However, it also requires rigorous due diligence to ensure the CMO's quality systems and compliance standards meet regulatory requirements.

Key Takeaways

Lisinopril’s supply chain is characterized by a significant concentration of API manufacturing in China and India, with finished dosage forms produced globally by numerous generic manufacturers. Regulatory compliance, particularly GMP standards and impurity control, is paramount for all supply chain participants. Key raw materials and intermediates must be reliably sourced for continuous API synthesis. Geopolitical factors, trade policies, and the strategic use of contract manufacturing organizations are critical considerations for ensuring a stable and cost-effective supply of lisinopril.

FAQs

1. What are the primary risks to the lisinopril supply chain? The primary risks include reliance on a limited number of API manufacturers, potential geopolitical instability in key manufacturing regions, regulatory changes concerning impurity limits, and disruptions in global shipping and logistics.
2. How can a company diversify its lisinopril API sourcing? Diversification involves identifying and qualifying alternative API suppliers in different geographic regions (e.g., India, Europe, alongside China), conducting thorough quality audits, and establishing robust contractual agreements.
3. What is the typical shelf life of lisinopril tablets? Lisinopril tablets typically have a shelf life of 24 to 36 months when stored under recommended conditions, as indicated by the manufacturer.
4. Are there any significant single-source dependencies for lisinopril API? While several companies manufacture lisinopril API, the market is relatively consolidated. Over-reliance on specific large-volume producers in China or India can represent a single-source dependency risk if those entities face production issues.
5. What impact do nitrosamine impurity concerns have on lisinopril supply? Regulatory scrutiny on nitrosamine impurities has led to increased testing requirements and potential manufacturing process modifications for various drugs, including lisinopril. Manufacturers must demonstrate robust control over potential sources of these impurities, which can affect production timelines and costs if remediation is required.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practices (GMP). Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-polices-guidances-drugs/good-manufacturing-practices-gmp

[2] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/scientific-advice-procedures/good-manufacturing-practice-gmp

[3] U.S. Food and Drug Administration. (2020, September 2). Nitrosamine Impurities: Q&A for Industry. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/nitrosamine-impurities-qa-industry